


## Cyclo(CKLIIF) TFA

<b>Cat. No.:</b>	HY-P10221A
<b>Molecular Formula:</b>	C <sub>38</sub> H <sub>60</sub> F <sub>3</sub> N <sub>7</sub> O <sub>8</sub> S
<b>Molecular Weight:</b>	831.99
<b>Sequence:</b>	Cyclo(Cys-Lys-Leu-Ile-Ile-Phe)
<b>Sequence Shortening:</b>	Cyclo(CKLIIF)
<b>Target:</b>	HIF/HIF Prolyl-Hydroxylase
<b>Pathway:</b>	Metabolic Enzyme/Protease
<b>Storage:</b>	Sealed storage, away from moisture
	Powder    -80°C    2 years
	-20°C    1 year



\* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : 100 mg/mL (120.19 mM; Need ultrasonic)

Concentration	Solvent	Mass	1 mg	5 mg	10 mg
			1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM		1.2019 mL	6.0097 mL	12.0194 mL
	5 mM		0.2404 mL	1.2019 mL	2.4039 mL
	10 mM		0.1202 mL	0.6010 mL	1.2019 mL

Please refer to the solubility information to select the appropriate solvent.

### BIOLOGICAL ACTIVITY

#### Description

Cyclo CKLIIF is a dual inhibitor for hypoxia inducible factor (HIF) 1 and 2, which disrupts the interaction of both HIF1- $\alpha$  and HIF2- $\alpha$  with HIF1- $\beta$ , with affinity for HIF1- $\alpha$  and HIF2- $\alpha$  PAS-B domains  $K_D$  of 2.6 and 2.2  $\mu$ M, respectively<sup>[1]</sup>.

### REFERENCES

[1]. Ball AT, et al., Identification and Development of Cyclic Peptide Inhibitors of Hypoxia Inducible Factors 1 and 2 That Disrupt Hypoxia-Response Signaling in Cancer Cells. J Am Chem Soc. 2024 Mar 19.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA